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Summary
We present a principled technique for estimating the effect of covariates on malaria parasite 
clearance rates in the presence of “lag” and “tail” phases through the use of a Bayesian 
hierarchical linear model. The hierarchical approach enables us to appropriately incorporate the 
uncertainty in both estimating clearance rates in patients and assessing the potential impact of 
covariates on these rates into the posterior intervals generated for the parameters associated with 
each covariate. Furthermore, it permits us to incorporate information about individuals for whom 
there exists only one observation time before censoring, which alleviates a systematic bias 
affecting inference when these individuals are excluded. We use a changepoint model to account 
for both lag and tail phases, and hence base our estimation of the parasite clearance rate only on 
observations within the decay phase. The Bayesian approach allows us to treat the delineation 
between lag, decay, and tail phases within an individual’s clearance profile as themselves being 
random variables, thus taking into account the additional uncertainty of boundaries between 
phases. We compare our method to existing methodology used in the antimalarial research 
community through a simulation study and show that it possesses desirable frequentist properties 
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for conducting inference. We use our methodology to measure the impact of several covariates on 
Plasmodium falciparum clearance rate data collected in 2009 and 2010. Though our method was 
developed with this application in mind, it can be easily applied to any biological system 
exhibiting these hindrances to estimation.
Keywords
Bayesian; changepoint models; clearance rate estimation; drug resistance; hierarchical linear 
models; left censoring; malaria; Plasmodium falciparum
1. Introduction
Resistance to antimalarial medication has been, and continues to be, a grave global health 
concern. Over the past 400 years, numerous drugs have initially shown promise as effective 
treatments against Plasmodium falciparum (the most lethal of the malaria parasites). 
Unfortunately, these malaria parasites have successively developed resistance to each drug, 
with time intervals between drug deployment and first reported resistance (that is adequately 
detected) ranging from 278 years (quinine) to less than 1 year (sulfadoxine-pyrimethamine). 
For a detailed history of the struggle to find an effective treatment regimen for P. falciparum 
malaria, see Wongsrichanalai et al. (2002).
Artemisinin, first established as an antimalarial drug in 1978, has proven extremely effective 
against malaria both individually and as part of “Artemisinin Combination Therapy” in 
which fast acting artemisinin is combined with a slower acting antimalarial partner drug 
(e.g., mefloquine, lumefantrine, or piperaquine); however, recent evidence suggests that P. 
falciparum resistance to artemisinin is developing in Southeast Asia (see Dondorp et al., 
2009; White, 2010; Amaratunga et al., 2012; Ashley et al., 2014). To accurately monitor the 
spread, independent emergence, or worsening of artemisinin resistance over time, 
researchers are interested in whether and to what extent patient level covariates are 
associated with resistance. Before one can answer these questions, a quantitative measure of 
antimalarial efficacy is required.
The parasite clearance rate is largely considered to be the most robust measure of 
artemisinin effect (Flegg et al., 2011; White, 2011). To calculate this rate, one first 
administers an artemisinin to an individual patient, and then counts the parasite density in 
the patient’s blood at a sequence of measurement times. The parasite clearance rate is then 
defined to be the negative of the slope of the log-parasitemia over the time in which the 
antimalarial is taking effect. Unfortunately, many factors make the calculation of this rate 
more complicated than it would appear to be.
Some individuals exhibit an initial period after artemisinin administration in which their 
parasite densities remain roughly constant, or even increase, rather than decrease as would 
be expected (Doolan et al., 2002; Koning, 2007). These “lag” phases are thought to be 
caused by a combination of different factors, including the absorption time of drugs; the 
cyclical nature of malarial pathology; schizogony, which would result in a rapid increase in 
parasitemia; and the relatively synchronous development of sequestered parasites in 
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microvessels, where they may be incidentally in the process of liberating new parasites into 
circulation at the same time artemisinin is administered (for example, see Dondorp et al., 
2005). Flegg et al. (2011) and Nkhoma et al. (2013) estimated that 30% and 25.7% of 
clearance profiles in their respective data sets appeared to have lag phases. At present, it is 
accepted that only the linear part of the log-parasitemia curve is a good measure of 
antimalarial susceptibility (Nkhoma et al., 2013), and hence this lag phase should not factor 
into the calculation of the clearance rate. Failure to account for lag phases can result in a 
downwardly biased estimates of clearance rates, as is demonstrated in Figure 1 (b) of 
Section 4.1.
Beyond the existence of lag phases, there are other aspects of parasite clearance profiles that 
are potentially inimical to estimation. Due to the data collection process there is a detection 
limit, which means that we cannot actually observe a parasite density below a certain value. 
Hence, there are observations over time which are left censored (i.e., we know that the 
patient had a parasite density that was lower than the detection limit, but do not know its 
actual value). Additionally, some profiles exhibit a bottoming out in which the observed 
parasite densities hover around the detection limit. These “tail” phases also are not typically 
factored into the calculation of the clearance rate, as they are not within the time frame 
where the parasite load is steadily decaying. Finally, there is the potential for measurement 
errors, caused primarily by the imprecise nature of the technique used to calculate parasite 
densities. See Dowling and Shute (1966) and O’Meara et al. (2005) for more on variability 
caused by the data collection process. Further, if we interpret the circulating parasite density 
as a measure of (i.e., as proportional to) the full parasite load within the body, then 
differences in the fraction of parasites sequestered in microvessels may lead to measurement 
error.
White (2011) motivates the need for a principled methodology for estimating clearance rates 
while accounting for lag and tail phases, stating that “it remains to be decided what should 
be the criteria for defining the top of the slope (i.e. maximum value, or intersection of linear 
fit to the initial plateau, or modelled fit), and for the lowest densities that should be included 
at the tail of the curve.” Towards this end, Flegg et al. (2011) developed the Parasite 
Clearance Estimator (PCE), a method for estimating the parasite clearance rate while 
accounting for lag phases, tail phases, and measurement errors. This method is the current 
standard for measuring clearance rates and represents an improvement over previous 
methodologies that simply fit a line to the log parasitemia over time for each individual and 
ignored data points which fell below the detection limit. To assess how often the PCE is 
used, we searched PubMed to find papers that reported parasite clearance for P. falciparum 
malaria infections between November, 2011 and May, 2014. 48 papers were found and 25 of 
them had frequent parasite data, suitable for the PCE tool; of these 25 papers, 17 (68%) used 
the PCE to estimate parasite clearance, showing that PCE is widely used in practice. For the 
PCE method, Flegg et al. (2011) provide a step-by-step algorithm for identifying tail phases, 
and lag phases. Tail phases are defined in terms of a series of thresholds, whereas lag phases 
are determined by comparing linear, quadratic, and cubic fits when possible and assessing 
certain characteristics of these fits. To account for the detection limit, tobit regression is 
used whenever possible.
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The PCE was developed with the sole objective of attaining clearance rate estimates for each 
patient, and has improved the estimation of clearance rates when this represents the primary 
end point of a study; however, the impact of patient level covariates on these clearance rates 
can be an important primary end point in other studies. A common approach taken in the 
antimalarial literature for conducting this latter analysis is the following two-stage 
procedure:
1. Estimate the clearance rate using the PCE
2. Estimate the effect of covariates on estimated clearance rate (or, equivalently, the 
half-life) through regression.
This approach has many shortcomings. Firstly, in using this two-stage approach the 
estimated clearance rates are treated as known in the second level, which drops all 
information about the variability in estimation. This variability differs in degree from 
individual to individual depending on the number of time points available. Hence, the 
standard approach uses homoskedastic errors when they are actually heteroskedastic, a 
problem which is known to potentially result in biased inference due to improper standard 
error estimates (White, 1980). Secondly, PCE handles profiles with a small number of 
measurement times in a way that can introduce substantial bias when conducting a second 
level regression. For individuals who had only one time recording before the detection limit 
was reached, the PCE cannot compute a clearance rate estimate and hence that individual is 
omitted from the analysis. Furthermore, for individuals with only two time measurements 
before censoring, the PCE replaces the censored observation with the censoring point, 
resulting in a clearance rate estimate that is biased downwards. The ramifications of these 
biases are discussed in Section 3.1. In addition, the methods for lag and tail detection used 
by PCE are quite complicated and are not derived from an underlying statistical model, 
which may bias both the estimates of the clearance rates and the estimates of covariate 
effects on these clearance rates. These factors are shown in Section 3.2 to result in 
confidence intervals that fail to meet their prescribed coverage guarantees and in estimators 
demonstrating substantial bias. For these reasons, a principled approach to address these 
issues in a way that produces statistically sound results is desired.
We model parasite clearance rates under the assumption that each observed time of an 
individual’s parasite density takes place in one of three phases: a lag phase, a decay phase, 
or a tail phase. Though we assume all profiles contain a decay phase, we allow for the 
possibility that certain individuals lack a lag phase, a tail phase, or both – consistent with 
what antimalarial researchers have observed. We also enforce continuity between the 
functions describing adjacent phases. To accomplish this analytical approach, we embed a 
changepoint model within a Bayesian hierarchical linear model. The hierarchical structure 
enables us to incorporate information about all patients, regardless of how many time points 
are available for their parasite clearance profile, and address the hindrances to estimation 
discussed earlier. The changepoint model determines whether or not a certain phase existed 
within an individual’s parasite clearance profile and isolates the time of transition between 
the phases if multiple phases occur. After giving a proper exposition of our model, we then 
show in a series of simulations the improvements our model provides relative to the standard 
two-stage approach in terms of desirable statistical properties. These included reduced mean 
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squared error of estimated clearance rates and the creation of intervals that have better 
frequentist properties. We then present the results of using this method to investigate the 
relationship between covariates and parasite clearance half-lives in Cambodian patients 
treated with artesunate (a type of artemisinin) for P. falciparum malaria in 2009 and 2010.
2. The Bayesian Clearance Estimator
We propose a Bayesian model for parasite densities over time that accounts for lag phases, 
tail phases, and censored observations.
2.1 Data Likelihood
Let yij denote the malarial parasite density for the ith individual at time tij, where 1 ≤ i ≤ N 
and 1 ≤ j ≤ ni, and let ti1, …, tini be the time points for the ith individual. Let  be the time of 
the changepoint between the lag and decay phase for the ith individual, and let  be the time 
of the changepoint between the decay phase and the tail phase. Our model for the data is:
where αi and βi are individual level parameters, and εij are the individual level errors. Hence, 
{βi} represent the clearance rates of interest.
We assume that the error terms represent biological variability and may possibly include 
measurement error of some type: . Note here that we assume independence 
between the errors at time tij and tik for all individuals i and all measurement numbers j ≠ k. 
We assess the validity of this assumption in Web Appendix A by looking at residuals from 
our data analysis.
A major concern among malarial researchers in fitting these profiles is the existence of 
“outlying” counts being recorded for individual that are biologically implausible and do not 
reflect the individual’s true parasite density. Such outliers often result from transcription 
errors (Flegg et al., 2011). These outlying observations have the potential to substantially 
impact the resultant fit. Flegg et al. (2011) developed an automated methodology for 
assessing whether or not each observed parasite count was scientifically feasible, and for 
removing them from the analysis before any profile fitting is done on these grounds, based 
on thresholds determined by scientists with subject matter experience (see the methodology 
supplement of Flegg et al. (2011) for details). We recommend that practitioners either 
examine each profile for outliers or use the automated methodology of Flegg et al. (2011) in 
determining whether an observed count is an outlier. We have built the Flegg et al. (2011) 
outlier detection schema into our methodology as an optional step to be undertaken before 
data analysis is conducted.
Due to the detection limit within the data collection process, we do not always observe the 
full set of parasite densities {yij}. Let ζ denote the detection threshold (two typical values of 
ζ are 40 parasites per microliter and 16 parasites per microliter, as described in Flegg et al. 
(2011)). Then, the actually observed counts, , are:
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2.2 Prior Distributions and Hierarchical Structure
We now specify prior distributions for our regression parameters and the outlier indicators. 
As part of the hierarchy for the {βi}, we note that in many cases we are interested in the 
relationship between {βi} and a host of covariates. We let X denote this N × p matrix of 
covariates. The case in which we do not have covariates is captured in this representation by 
simply letting X be an N × 1 vector of ones. Our priors are:
where p(·) represents a prior density function. Our specification of lognormal priors on the 
clearance rates is in line with the standard analyses performed by antimalarial researchers 
and result in an analysis that is highly reminiscent of a random effects model. Our priors on 
{γ, } and {η, } are specified so that we have proper posterior distributions, avoiding the 
trap described in Hobert and Casella (1996) and following the recommendations of Gelman 
(2006). We place the Jeffrey’s prior on . All told, this specification results in shrinkage 
estimation for the {βi}, with the degree and direction of the shrinkage aided and influenced 
by the individual level covariates. The posterior distribution of γ is the primary focus of 
posterior inference, as γ represents the effect of the covariates of interest on the clearance 
rates.
We introduce two probabilities, πℓ and πτ, which represent the a priori probabilities of there 
being a lag phase and a tail phase respectively. If there is not a lag phase for individual i, 
then the changepoint between lag and decay phase, , occurs at time 0 with probability 1. If 
there is a lag phase, then we specify a prior distribution over the observed time domain for 
the ith individual. The specification of priors on the tail phase is similar. If there is no tail 
phase, then the changepoint between the decay and tail phases occurs at the maximal time 
point for that individual, tini, with probability 1. Otherwise, we specify a prior for  over its 
feasible range given the constraint that .
Traditionally, Bayesian changepoint models have used uniform priors for the location of 
changepoints; see Bacon and Watts (1971); Smith and Cook (1980); Carlin et al. (1992) 
among many. A uniform prior would have the unrealistic characteristic in our application of 
putting equal prior probability on changepoints near and far from the boundary, making it 
unappealing. In our application changepoints can be thought of as time-to-event quantities, 
which are commonly modeled by exponential distributions (resulting in a constant hazard 
rate over time). We note that the exponential distribution has a mode at 0 for any value of 
the rate parameter. This type of model would be appropriate if it was believed that all 
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individuals had lag phases, just to varying degrees; however, antimalarial researchers 
believe that some individuals truly do not have lag phases, and that those with lag phases 
have modal changepoint values strictly away from zero.
We instead place hierarchical log-normal priors on  and on  (as tail phases tend to 
happen at the end of the trajectory, information should be pooled relative to distance from 
the last measurement time). This is a slight modification of Lange et al. (1992) and Slate and 
Turnbull (2000), wherein the use of hierarchical normal priors for changepoints is 
advocated. Hierarchical log-normal priors allow for different hazard rates at different time 
values and sharing of information between the observed clearance profiles while restricting 
the changepoints to take on positive values. The log-normal distribution also has its mode 
away from the boundary and can accommodate a long right tail, which is often found in 
studying time-to-event quantities. Our priors are:
For the hyperparameters a, b, c2, d2, we place proper yet diffuse priors to allow for posterior 
propriety. Past research suggests that lag and tail phases most commonly persist for around 6 
hours (Flegg et al., 2011). We incorporate this information, and say that a, b = (log(6), 
0.52), resulting in a 95% prior range of [2.2, 16] for the value of the median. We place 
Inverse Gamma(1, 1) priors on c2 and d2, allowing for substantial variability about the prior 
fit. Our priors on πℓ and πτ; are πℓ, πτ~Beta(1, 1). In Web Appendix B, we prove the 
propriety of the posterior distribution that results from our choice of prior distributions. In 
Web Appendix C, we describe a Gibbs sampling algorithm for attaining samples from the 
resulting posterior distribution. The simulation studies of Section 3 assess the robustness of 
our priors on lag and tail phases against misspecification of the lag and tail phase generative 
distribution when estimating the impact of the covariates of interest on clearance rates. In 
Web Appendix E, we perform a comparison of estimators produced by the log-normal and 
uniform both in simulation studies and in the data set analyzed in Section 4.
3. Comparison of Bayesian Methodology to the Standard Analysis
We now turn our attention to a detailed comparison of the Bayesian estimator to the standard 
two-stage analysis combining PCE with linear regression when the goal is the analysis of the 
effect of covariates via regression. We present a series of simulation studies that compare 
performance of the two methodologies under various data generative models. In these 
simulation studies, we simulate parasite clearance profiles that closely resemble those 
observed in real data by choosing parameter values based on those in the data set that we 
will be analyzing. The reason for this is that the PCE is specifically catered towards P. 
falciparum data, and incorporates “sanity” checks into its estimation procedure. Even though 
our method is generalizable to any scenario in which lag and tail phases are observed, we 
simulated as such to make the comparison as fair as possible. We focus herein on coverage 
of the resultant intervals from the two methods, as here valid frequentist inference is the 
primary objective.
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3.1 Bias Due to Sparse Number of Measurement Times
As was discussed in Section 1, a two-stage approach is typically used when analyzing the 
effect of covariates on clearance rates. One drawback of the two-stage analysis is that 
information is dropped on subjects for whom the PCE could not estimate a clearance rate. 
These subjects would include those whose parasite count is zero at the first observed time 
point after drug administration. Additionally, if the individual only has two time points 
before censoring the PCE replaces that censored observation with the detection limit. This 
results in a loss of information and can create a substantial bias. We present an example of 
the bias. Consider the following model:
We let  and . The 
values for the variances of xi, ui, and vi were chosen based on real data. For each individual, 
we “sampled” every 12 hours until a zero parasitema was recorded. We used a density of 40 
parasites per microliter of blood as the detection limit for this simulation.
In this simulation, the covariate xi is observed for each individual, but the ui and vi are 
unobserved errors. By construction, the covariate xi has no effect on the clearance rate, 
meaning the true coefficient for its slope should be zero; however, it is positively correlated 
with the initial parasite density. The lower an individual’s initial parasite density, the lower 
one’s clearance rate needs to be such that we do not have a zero parasite count in the first 
measurement time after treatment (i.e, such that the individual is not omitted from the 
analysis). This induces a spurious positive correlation between the clearance rates and the 
covariate xi if we use the conventional two-stage analysis. For individuals where PCE would 
replace censored observations by the detection limit, the same spuriously positive 
correlation exists. Replacing the censored observation by the detection limit would result in 
a negatively biased estimate of the clearance rate, and this replacement is more likely for 
lower values of xi. The Bayesian methodology suffers less from this bias, as we are able to 
estimate clearance rates by borrowing information from the other profiles, rather than being 
forced to drop individuals or to replace censored observations by the detection limit.
To show this bias, we simulated from the above model 1000 times, having 60 individuals 
present within each simulation. The results are shown in Table1. As can be seen, the two-
stage procedure is substantially biased, and results in 95% confidence intervals that fail to 
meet their coverage guarantees. The Bayesian estimator is able to overcome these issues, 
producing an unbiased estimate of the slope on xi and credible intervals that have good 
frequentist coverage. The Bayesian estimator had an estimated mean squared error of 0.163, 
which represents a reduction by roughly 75% over the mean squared error of the two-stage 
estimator (0.638). This also demonstrates that the additional flexibility our model provides 
by allowing for lag and tail phases does not corrupt the properties of our estimator when lag 
and tail phases are not present.
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Our data generative model in this simulation study resulted in 5% of profiles being omitted 
entirely and in 49% of profiles having their censored observation replaced by the detection 
limit when clearance rates were estimated using the PCE as part of the two-stage method. 
The sparsity of measurement times in this simulation is quite extreme relative to what is 
found in typical data sets, and hence it is likely that the extent of biases in typical data sets 
are not as extreme as those found here. In fact, a data set exhibiting such sparsity would 
likely be discarded as useless. This simulation helps to elucidate an important pitfall of the 
standard two-stage analysis. Furthermore, it shows that even in a sparse situation, the 
Bayesian estimator can result in valid inference.
3.2 Behavior of Estimators with a Sufficient Number of Measurement Times
As was previously shown, the omission of profiles with too few measurement times can lead 
to a bias in the estimation of the effect of covariates on clearance rates. We would also like 
to assess the coverage properties of intervals created in the absence of this issue. To do this, 
we simulated from a model with two populations where each population shares a common 
average initial parasite density but has a distinct average clearance rate. We sample 30 
people from each population in each simulation, for a total sample size of 60. In each 
simulation, we assess how well the respective methods are able to estimate the true 
difference on the log scale (i.e, the log of the ratio) between the true clearance rates for the 
two populations in terms of unbiasedness, and furthermore test the coverage of intervals 
created by both methods. We conducted three different simulation studies within this 
framework, with each study having different rates of lag and tail phase occurrence. We 
simulated 1000 data sets per set of lag and tail phase occurrences. Our data generative model 
is:
We let  and . Xi is either [1, 0] or [1, 
1] depending on which population individual i is from. We set γ= [log(0.15), 
log(0.25/0.15)]T, resulting in population average log clearance rates log(0.15) and log(0.25) 
respectively. In the simulation, we sampled every 6 hours until a parasite density is observed 
below the censoring limit (again, this is how the data are collected in practice). We made the 
sampling at every 6 hours to ensure ourselves that profiles would have more than three time 
points apiece such that we avoid the biases mentioned in Section 3.1. We used a detection 
limit of 16 parasites per microliter of blood. In all three simulation set-ups, all of the profiles 
simulated had more than three time points, thus indicating that we were successful in 
removing the main cause of the bias discussed in Section 3.1
Table 2 presents the results of our simulation studies. We found that in all three scenarios, 
the Bayesian estimator outperformed the standard two-stage estimator in terms of mean 
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squared error, coverage of intervals, and length of intervals. These gains were negligible in 
the model without lag and tail phases (Simulation 1), but were substantial once lag and tail 
phases were added to the data generative model (Simulations 2 and 3). The percent 
reductions in mean squared error for estimation via the Bayesian method versus the two-
stage method were 6.5%, 48.5%, and 80.1% respectively for the simulation studies. These 
results further show the robustness of our procedure against misspecification of the lag and 
tail phase generative process. Simulation 1 does not have any lag and tail phases, while 
Simulations 2 and 3 not only generate changepoints from a normal versus our specified log-
normal distribution, but also center the tail phase change points at a common mean 
regardless of distance from the last measurement time (which is how we have modeled 
them).
3.3 Small Sample Simulations
The simulations of Sections 3.1 and 3.2 are conducted with a moderate sample size. One 
may be concerned that with smaller sample sizes, our prior specifications may substantially 
bias the resulting estimators and corrupt the coverage properties of the resulting intervals. In 
Web Appendix D, we show that this is not the case with n = 20 individuals. Our estimators 
continue to outperform those of the two-stage analysis, resulting in marked reduction in 
mean squared errors and in interval lengths.
4. Analysis of Plasmodium falciparum Clearance Data
We now use data previously analyzed in Amaratunga et al. (2012) as a demonstration of our 
methodology. These data consist of P. falciparum clearance profiles measured in 2009 and 
2010 in Western Cambodia, an area where artemisinin resistance is well established, along 
with individual level covariates. Among other research objectives, the relationship between 
these covariates and half-life values (calculated as log(2)/(Clearance Rate)) was of interest. 
See Amaratunga et al. (2012) for an in depth description of the data set and its collection 
process. Data on 110 patients were available for this analysis, and parasite densities were 
measured every 6 hours. The censoring limit for this data collection was 15 parasites per 
microliter. All 110 individuals were recorded until no parasites were found in the collected 
blood smear (i.e., until left censoring occurred). Initial parasite counts also varied 
substantially across individuals, with a geometric mean of 58,130 parasites per microliter of 
blood, a mean of 89,225 parasites per microliter and a standard deviation of 99,413. The 
minimal initial parasite count was 10,240 parasites per microliter of blood, and the maximal 
initial parasite count was 546,460 parasites per microliter. As such, the total number of 
observation times varied substantially from individual to individual. On average, we had 
13.25 time measurments per individual with a standard deviation of 3.25. The minimal 
number of time measurements for an individual was 5, and the maximal number of time 
measurements was 22.
One point of interest was whether or not there is evidence of resistance to artemisinins 
developing over time. As such, indicator variables for the year of data collection were 
included. The coefficients on these indicators thus facilitate inference on whether the median 
clearance rate is decreasing over time. Researchers also wanted to investigate whether 
certain aspects of host genetics impact the resulting half-lives. As discussed in Amaratunga 
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et al. (2012), it has been theorized that red blood cell polymorphisms – including 
hemoglobin E (HbE), α-thalassaemia, and G6PD deficiency - may act to strengthen the pro-
oxidant activity of parasite defenses against artemisinins, hence resulting in lower clearance 
rates. To investigate this hypothesis, indicators were included for the existence of these three 
genetic factors. Additionally, parasites were broken into two genetically different groups 
(labeled group 1 and group 2), and group membership was included as a variable to see 
whether or not one particular group seemed more or less resistant to the antimalarial 
regimen; see Amaratunga et al. (2012) for details on how the groups were determined. 
Finally, the study wanted to assess the extent to which acquired immunity to the effects of P. 
falciparum may impact half-lives. As proxies for immunity, three covariates were included 
that are thought to correspond to increased likelihood of previous exposure to these malarial 
parasites. These were gender, whether an individual was 21 years of age or older versus 
younger than 21, and whether an individual was from the Kravanh or Veal Veng districts or 
not from those districts, as those two districts are heavily forested areas where malaria is 
transmitted (Amaratunga et al., 2012).
We first used the outlier detection methodology suggested in Flegg et al. (2011), and found 
that no observed counts were identified as outliers. We then ran our Gibbs sampling 
algorithm on this data set from six different starting locations, for 50,500 iterations per 
starting location. We show traceplots and autocorrelation function plots for a few of our 
parameters in Web Appendix F. Looking at the traceplots and autocorrelations, it is evident 
that our posterior samples take some time to reach stationarity and are correlated initially. 
As such, we discarded the first 500 iterations as burnin for each chain, and then thinned each 
chain by only keeping one out of every 100 iterations. The traceplots and autocorrelations 
after doing this are also included in Web Appendix E, and indicate that stationarity has been 
attained. In total, these six chains provided 3000 roughly independent posterior samples. The 
Gibbs Sampler was written in R (R Core Team, 2015), and is computationally intense. 
Sampling each of these six chains took 32 hours on a desktop computer with a 3.40 GHz 
processor and 16.0 GB RAM.
With our posterior samples now attained, we can conduct our posterior inference. Our 
analysis will focus on two aspects of the resultant posterior distributions. We will first 
investigate the ability of our method to fit individual level parasite profiles, including the 
detection of lag and tail phases. We will then provide intervals for the impact of our 
covariates of interest on the individual level P. falciparum half-lives after the administration 
of an antimalarial regimen.
4.1 Posterior Analysis of Individual Level Fits
Our methodology allows us to appropriately account for randomness in all aspects of the 
individual level parasite profiles. We can, for each individual, provide credible intervals for 
that individual’s clearance rate, pointwise credible bands for that individual’s true 
underlying parasite trajectory, and posterior predictive bands for the expected parasite 
counts at unobserved time points. We can also assess the frequency with which our model 
identified that an individual’s profile had lag phases and/or tail phases present.
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Our posterior distribution indicates that lag phases are more prevalent in our data set than 
substantial tail phases. 28.2% of individuals were identified as having median lag phases of 
longer than 3 hours, and 12.7% of individuals had lag phases longer than 6 hours (the first 
measurement time after drug administration). Conversely, only 2 of the 110 individuals were 
identified as having a tail phase (based on their median changepoint between decay phase 
and tail phase).
Figure 1 (a) shows an individual whose profile seems to exhibit only a decay phase, whereas 
Figure 1 (b) shows an individual that is identified as having a lag phase before the decay 
occurs. To illustrate the type of individual level analysis possible through our method, we 
will now describe various attributes of the posterior distribution for these two individuals’ 
parasite profiles.
For the individual in Figure 1 (a), the posterior mean clearance rate was 0.169, with a 95% 
credible interval of [0.1432, 0.1969]. Only 7.6% of the posterior samples identified this 
individual as having a lag phase of more than 3 hours, and only 1% identified a lag phase of 
greater than 6 hours. 1.9% identified that a tail phase existed.
The posterior mean clearance rate for the individual in Figure 1 (b) was 0.123, with a 95% 
credible interval of [0.1019, 0.1455]. 99.3% of the posterior samples identified that this 
individual had a lag phase exceeding 6 hours, but only 1% identified that this individual had 
a tail phase. The posterior mean of the changepoint between lag phase and decay phase for 
this individual was at time 25.2, with a 95% credible interval of [14.55, 32.94].
Figure 1 also includes the clearance estimate that would have been attained using a tobit 
regression if lag phases and tail phases were not accounted for (the dashed lines). For the 
individual in Figure 1 (a), the estimates are similar as this individual’s profile doesn’t seem 
to exhibit lag or tail phases; however, the clearance rate estimate attained for the individual 
in Figure 1 (b) is substantially lower (0.0907, with a 95% confidence interval of [0.073, 
0.108]). This provides further evidence that analyses not taking lag and tail phases into 
account could potentially be misleading.
4.2 Posterior Analysis of Covariate Impact
Table 3 displays our estimates for the impact of the covariates of interest on the log half-
lives, along with the 95% posterior intervals. Note that although our method originally 
regressed log clearance rates rather than log half-lives on the covariates of interest, we can 
attain the slopes for a regression on the log half-lives since log(Half-Life) = log(log(2)) – 
log(Clearance Rate). The exponential of these coefficients have the interpretation of, all else 
equal, the factor increase in the median half-life caused by increasing the value of the 
covariate by 1 unit. For example, the slope of 0.191 on the indicator variable for male means 
that males have a median half life larger than that of females by a factor of e0.191 = 1.21. We 
also report the standard 95% confidence intervals that a researcher would attain via the 
standard methodology (using the PCE to estimate the clearance rates) in Table 3. Though in 
general credible intervals and confidence intervals need not coincide, we deem it appropriate 
to use credible intervals to assess significance in the frequentist sense, just as a researcher 
would do with confidence intervals. We support this by noting the non-informative nature of 
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our priors and the results of the simulations in Section 3, which showed time and time again 
that our 95% Bayesian intervals achieved coverage very close to 95%, even as we varied the 
number of measurement times per individual and the true rates of lag and tail phases. An 
alternative approach would be to use the standard Bayesian paradigm for hypothesis testing, 
by placing prior probabilities on hypotheses and assessing Bayes factors.
We have evidence to suggest that sex and parasite group membership has a significant 
impact on parasite half lives at significance level α = 0.05, with Parasite Group 1 and males 
appearing to have a longer half-life. We note that if we take multiple comparisons into 
account and run these tests using a Bonferroni corrected significance level of α = 0.05/9 (the 
number of covariates), the results becomes insignificant, with an interval of [−0.075, 0.447] 
for gender and [−0.024, 0.332] for parasite group. We have no evidence to suggest that any 
of the other included covariates have a significant impact the Log Half-Lives; however, for 
the indicator variables for hemoglobin E our credible interval comes very close to not 
covering 0. The results of the two-stage analysis provided in Table 3 are slightly different 
from those given in Amaratunga et al. (2012) [Supplementary Web Appendix, Appendix 3] 
based on the two-stage method, as there the regression was done on the half-lives rather than 
their logarithms. We notice that at least with this data set, the estimates and confidence 
intervals attained via the two-stage method tend to resemble those attained via the Bayesian 
methodology, although nontrivial discrepancies between the two do exist. Nonetheless, our 
simulations in Section 3 show that there are times in which the discrepancy between the two 
methodologies could be quite substantial, and that the Bayesian methodology presented 
herein results in estimators with better behavior in terms of bias, variance, and length of 
parameter interval.
4.3 Model Diagnostics
In Web Appendix A, we include two model checks based on our posteriorpredictive 
distribution. In the first, we check the coverage of pointwise 95% posterior predictive ranges 
for the log parasite profiles for each individual. In the second, we check whether or not our 
assumption of independence between errors within a parasite profile is reasonable given the 
data at hand. As is discussed in Web Appendix A, neither of these posterior predictive 
checks raised cause for concern, lending credence to the model based inference presented in 
this work.
5. Discussion
Our method is quite general, in that it does not try to capture the occurrences of lag and tail 
phases mechanistically. Different drugs may target different malarial life cycle stages and 
this could affect the existence and magnitude of lag and tail phases. A model derived with 
one particular antimalarial in mind may not be useful for other antimalarial regimens, a trap 
which our model avoids. It also allows for extensions of our methods to other biological 
systems exhibiting lag and tail phases. Our model can also readily facilitate hypothesis 
testing for the existence of lag and tail phases within certain populations through a 
comparison of Bayes factors for models that allow for lag and tail phases with those that do 
not. A model without lag and tail phases can be attained by deterministically setting πℓ = 0 
and πτ = 0.
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We believe that this methodology may prove useful to researchers interested in clearance 
rate analysis of malarial parasites, as well as other parasites, viruses, and bacteria. As we 
have shown, our methodology provides a framework for investigating which factors affect 
clearance rates, and effectively uses shrinkage estimation and changepoint models to result 
in valid statistical inference.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Examples of posterior log parasitemia profiles. The first profile (a) is identified as only 
having a decay phase, whereas the second (b) is identified as having a lag phase before the 
decay occurs. The gray lines are various posterior samples. The solid black line represents 
the posterior mean clearance rate from our Bayesian procedure. The dotted black line is the 
fit given by the PCE. The dashed black line is the fit given by a simple to bit regression 
without lag and tail phases. The triangles are censored observations due to the detection 
limit
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Table 1
Results from the simulation studies of Section 3.1. The true value of γx, the slope coefficient on xi for 
predicting the clearance rates, is 0. From left the right, the columns represent the average value and standard 
deviation of the two-stage estimator across simulations; the average value and standard deviation of the 
Bayesian estimator across simulations; the percentage reduction in average loss (under squared error loss) 
attained by using the Bayesian estimator; the proportion of 95% intervals from the two-stage method that 
capture the true difference in means and length of those intervals; and the proportion of 95% intervals from the 
Bayesian method that capture the true difference in means and the length of those intervals
(SD)  (SD) % Red. in Avg. Loss  (Length)  (Length)
0.755 (0.261) −0.05 (0.40) 74.5% 24.6% (1.04) 94.6% (1.57)
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